Arzol Chemical Company

Arzol is a preclinical-stage biotechnology company focused on the discovery and development of novel small molecule inhibitors for the treatment of cancer. The company's primary research centers on targeting ribonucleotide reductase (RNR), a critical enzyme in DNA synthesis and repair that is frequently overexpressed in aggressive and treatment-resistant tumors. Arzol's lead candidates, such as ARZ-001, are designed to provide superior potency and selectivity compared to traditional RNR inhibitors like hydroxyurea. By leveraging proprietary chemical scaffolds, the company aims to address high-unmet-need malignancies, including glioblastoma and pancreatic ductal adenocarcinoma. Arzol is a spin-out from the University of Michigan and is currently advancing its lead programs through IND-enabling studies.